The DOI matches its Crossref record.
Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial
Open accessAbstract
days with no symptomatic eVect or objective change in his AIMS score.In April 1997 ventral thalamotomy was performed on the right side in two stages under local anaesthesia.A Bennett spheroid guide had previously been inserted under general anaesthesia using CT guidance and a Leksell frame.Details of the lesions are shown in the table.The first lesion was relatively anterior and it reduced the torticollis, neck pain, hypertonia, and the dyskinesia of the contralateral limbs and allowed him to smile and laugh.One week later a second lesion was placed posteriomedial to the first.This abolished the residual "cogwheeling" of the left upper limb and improved his dexterity.There were no surgical complications.Postoperative MRI (figure) 8 months after the procedure confirms the position of the two lesions in the right thalamus.Twelve months later the patient remains well with minimal dystonic neck movements and no evidence of abnormal posturing of the left arm and oV all medication.His AIMS score is now 8/40.Although the eYcacy of thalamotomy has long been recognised in secondary dystonia 6 we are not aware of any reports of its use in drug induced dystonia.The mechanism of drug induced dystonia is not yet known and extrapolating the surgical results for treatment of dystonia of other aetiologies may not be appropriate.The reported mortality from thalamotomy ranges from 0.4% to 6%. 2 Recent experience with pallidotomy indicates an incidence of severe clinical complications of between 2%-8%. 2 Because of the proximity of the optic tract to the globus pallidus persistent visual defects are a well known risk of pallidotomy, up to 14% in one series. 3 It is too early to be certain of long term eYcacy but 12 months after operation the patient remains well and oV all medication.We conclude that thalamotomy should also be considered in patients with medically refractory drug induced tardive dystonia and dyskinesia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations
Dworkin, R. H., Backonja, M., Rowbotham, M. C., Allen, R. R., Argoff, C. R., Bennett, G. J., Bushnell, M. C., Farrar, J. T., Galer, B. S., Haythornthwaite, J. A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.11.1524 · Cited by 1,216
Diabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & McQuay, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub2 · Cited by 690
Bril, V., England, J., Franklin, G. M., Backonja, M., Cohen, J., Del Toro, D., Feldman, E., Iverson, D. J., Perkins, B., Russell, J. W., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166ebe · Cited by 634
Gabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561
Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study
Garcia-Borreguero, D., Larrosa, O., de la Llave, Y., Verger, K., Masramon, X., & Hernandez, G. (2002) · Neurology · doi:10.1212/wnl.59.10.1573 · Cited by 405
Anticonvulsant drugs for acute and chronic pain
Wiffen, P. J., Collins, S., McQuay, H. J., Carroll, D., Jadad, A., & Moore, R. A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001133.pub2 · Cited by 392
RetractedOutcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0906126 · Cited by 361
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
Steinman, M. A., Bero, L. A., Chren, M.-M., & Landefeld, C. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00008 · Cited by 336
Anticonvulsants for Neuropathic Pain Syndromes: Mechanisms of Action and Place in Therapy
Tremont-Lukats, I. W., Megeff, C., & Backonja, M.-M. (2000) · Drugs · doi:10.2165/00003495-200060050-00005 · Cited by 330
Freeman, R., Durso-DeCruz, E., & Emir, B. (2008) · Diabetes Care · doi:10.2337/dc07-2105 · Cited by 322
Anticonvulsants in neuropathic pain: rationale and clinical evidence
Jensen, T. S. (2002) · European Journal of Pain · doi:10.1053/eujp.2001.0324 · Cited by 305
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Pharmacologic treatment of pain in polyneuropathy
Sindrup, S. H., & Jensen, T. S. (2000) · Neurology · doi:10.1212/wnl.55.7.915 · Cited by 296
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & Rice, A. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub3 · Cited by 292
Distal Symmetric Polyneuropathy: A Review
Callaghan, B. C., Price, R. S., & Feldman, E. L. (2015) · JAMA · doi:10.1001/jama.2015.13611 · Cited by 289
Mendell, J. R., & Sahenk, Z. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp022282 · Cited by 270
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
“Further smaller studies have found gabapentin to be more effective than placebo at maximum doses of 1200 mg [48] and 3600 mg [49], but not 900 mg/day [50].”
BackgroundCepeda, M. S., Berlin, J. A., Gao, C. Y., Wiegand, F., & Wada, D. R. (2012) · Pain Medicine · doi:10.1111/j.1526-4637.2012.01340.x · Cited by 71
Fleet, J. L., Dixon, S. N., Kuwornu, P. J., Dev, V. K., Montero-Odasso, M., Burneo, J., & Garg, A. X. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193134 · Cited by 60
Chou, R., Carson, S., & Chan, B. K. S. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0877-5 · Cited by 57
Metadata
- Authors
- GORSON, K. C., SCHOTT, C., HERMAN, R., ROPPER, A. H., & RAND, W. M.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 1999-02-01
- Volume
- 66
- Issue
- 2
- Pages
- 251-252
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2071357308
- Cited by
- 206
- References
- 0
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.